The influence of remimazolam on the reversal of rocuronium-induced neuromuscular blockade with sugammadex

JRCT ID: jRCT1071230073

Registered date:12/10/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Patients scheduled for elective surgery under general anesthesia
• Date of first enrollment: 31/10/2023
• Target sample size: 30
• Study type: Interventional
• Intervention(s): assignment

Outcome(s)

• Primary Outcome: Time from sugamadex administration to TOF ratio 0.90 and more
• Secondary Outcome: Time from initial rocuronium administration to TOF count 0, to reappearance of T1 and T2, and total rocuronium dose used during the surgery.

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: Patients over 18 years old scheduled for elective surgery under general anesthesia. All patients were American Society of Anesthesiologists physical status class I or II.
• Exclude criteria: Patients under 18 years old, emergency surgery, obesity (BMI 30 kg/m2 and more), with hepatic and renal dysfunction, with neuromuscular disorder, with contraindication to benzodiazepine

Related Information

• Primary Sponsor: Fujimoto Masafumi